Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study

被引：9
|
作者：
Moreau, Philippe [1 ]
Ghori, Razi [2 ]
Farooqui, Mohammed [2 ]
Marinello, Patricia [2 ]
San Miguel, Jesus [3 ]
机构：
[1] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France
[2] Merck & Co Inc, Dept Med Oncol, Kenilworth, NJ USA
[3] Clin Univ Navarra, CIMA, IDISNA, CIBERONC,Dept Clin & Translat Med, Pamplona, Spain
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 194卷 / 01期
关键词：
multiple myeloma; immunotherapy; oncology; IMMUNOTHERAPY;
D O I：
10.1111/bjh.17448
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E48 / E51
页数：4
相关论文
共 50 条
  • [21] Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study
    Iida, Shinsuke
    Watanabe, Takashi
    Matsumoto, Morio
    Suzuki, Kenshi
    Sunami, Kazutaka
    Ishida, Tadao
    Ando, Kiyoshi
    Chou, Takaaki
    Ozaki, Shuji
    Taniwaki, Masafumi
    Uike, Naokuni
    Shibayama, Hirohiko
    Hatake, Kiyohiko
    Izutsu, Koji
    Ishikawa, Takayuki
    Shumiya, Yoshihisa
    Tobinai, Kensei
    CANCER SCIENCE, 2019, 110 (09) : 2924 - 2932
  • [22] Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
    Dytfeld, Dominik
    Jasielec, Jagoda
    Griffith, Kent A.
    Lebovic, Daniel
    Vesole, David H.
    Jagannath, Sundar
    Al-Zoubi, Ammar
    Anderson, Tara
    Detweiler-Short, Kristen
    Stockerl-Goldstein, Keith
    Ahmed, Asra
    Jobkar, Terri
    Durecki, Diane E.
    McDonnell, Kathryn
    Mietzel, Melissa
    Couriel, Daniel
    Kaminski, Mark
    Vij, Ravi
    Jakubowiak, Andrzej J.
    HAEMATOLOGICA, 2014, 99 (09) : E162 - E164
  • [23] Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients
    Morio Matsumoto
    Kenshi Suzuki
    Junya Kuroda
    Masafumi Taniwaki
    Kazutaka Sunami
    Hiroshi Kosugi
    Kiyoshi Ando
    Dai Maruyama
    Kensei Tobinai
    Uma Kher
    Mohammed Farooqui
    Jason Liao
    Patricia Marinello
    Kenji Matsuda
    Yasuhiro Koh
    Takashi Shimamoto
    Shinsuke Iida
    International Journal of Hematology, 2021, 113 : 777 - 784
  • [24] The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
    Hashimoto, Shigeo
    Kuroha, Takashi
    Yano, Toshio
    Sato, Naoko
    Furukawa, Tatsuo
    INTERNAL MEDICINE, 2016, 55 (20) : 3025 - 3028
  • [25] Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy
    Quach, Hang
    Nooka, Ajay
    Samoylova, Olga
    Venner, Christopher P.
    Kim, Kihyun
    Facon, Thierry
    Spencer, Andrew
    Usmani, Saad Z.
    Grosicki, Sebastian
    Suzuki, Kenshi
    Delimpasi, Sosana
    Weisel, Katja
    Obreja, Mihaela
    Zahlten-Kumeli, Anita
    Mateos, Maria-Victoria
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (04) : 784 - 788
  • [26] Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients
    Matsumoto, Morio
    Suzuki, Kenshi
    Kuroda, Junya
    Taniwaki, Masafumi
    Sunami, Kazutaka
    Kosugi, Hiroshi
    Ando, Kiyoshi
    Maruyama, Dai
    Tobinai, Kensei
    Kher, Uma
    Farooqui, Mohammed
    Liao, Jason
    Marinello, Patricia
    Matsuda, Kenji
    Koh, Yasuhiro
    Shimamoto, Takashi
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (06) : 777 - 784
  • [27] Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
    Weisel, Katja
    Dimopoulos, Meletios
    Moreau, Philippe
    Yagci, Munci
    Larocca, Alessandra
    Kanate, Abraham S.
    Vural, Filiz
    Cascavilla, Nicola
    Basu, Supratik
    Johnson, Peter
    Byeff, Peter
    Hus, Marek
    Rodriguez-Otero, Paula
    Muelduer, Ercan
    Anttila, Pekka
    Hayden, Patrick J.
    Krauth, Maria-Theresa
    Lucio, Paulo
    Ben-Yehuda, Dina
    Mendeleeva, Larisa
    Guo, Shien
    Yu, Xin
    Grote, Lara
    Biyukov, Tsvetan
    Dhanasiri, Sujith
    Richardson, Paul
    LEUKEMIA & LYMPHOMA, 2020, 61 (08) : 1850 - 1859
  • [28] Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma
    Popat, Rakesh
    Oakervee, Heather
    Williams, Catherine
    Cook, Mark
    Craddock, Charles
    Basu, Supratik
    Singer, Charles
    Harding, Stephen
    Foot, Nicola
    Hallam, Simon
    Odeh, Liz
    Joel, Simon
    Cavenagh, Jamie
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (06) : 887 - 894
  • [29] Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma
    Kobayashi, Tsutomu
    Kuroda, Junya
    Fuchida, Shin-ichi
    Kaneko, Hitomi
    Yagi, Hideo
    Shibayama, Hirohiko
    Tanaka, Hirokazu
    Kosugi, Satoru
    Uoshima, Nobuhiko
    Kobayashi, Masayuki
    Adachi, Yoko
    Ohta, Kensuke
    Ishii, Kazuyoshi
    Uchiyama, Hitoji
    Matsuda, Mitsuhiro
    Nakatani, Eiji
    Tsudo, Mitsuru
    Shimazaki, Chihiro
    Takaori-Kondo, Akifumi
    Nomura, Shosaku
    Matsumura, Itaru
    Taniwaki, Masafumi
    Kanakura, Yuzuru
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (01) : 37 - 45
  • [30] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Victoria Mateos, Maria
    Prosper, Felipe
    Martin Sanchez, Jesus
    Ocio, Enrique M.
    Oriol, Albert
    Motllo, Cristina
    Michot, Jean-Marie
    Jarque, Isidro
    Iglesias, Rebeca
    Sole, Maria
    Martinez, Sara
    Kahatt, Carmen
    Fudio, Salvador
    Corral, Gema
    Zeaiter, Ali
    Montilla, Lola
    Ribrag, Vincent
    CANCER MEDICINE, 2023, 12 (04): : 3999 - 4009
12345